Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.3M Sell
161,000
-140,700
-47% -$7.28M 0.02% 521
2026
Q1
$15.3M Sell
301,700
-241,800
-44% -$11.3M 0.04% 436
2025
Q4
$16M Buy
543,500
+24,500
+5% +$666K 0.03% 447
2025
Q3
$13.4M Sell
519,000
-327,400
-39% -$9.13M 0.02% 561
2025
Q2
$23.4M Buy
846,400
+179,400
+27% +$4.72M 0.04% 347
2025
Q1
$18.9M Buy
667,000
+276,600
+71% +$9.82M 0.04% 355
2024
Q4
$16.2M Buy
+390,400
New +$18.7M 0.03% 389

Other funds holding MRNA

PEAK6's MRNA Position: Q2 2026 in Review

PEAK6 sold out of Moderna (MRNA) in Q2 2026, closing a stake of 60,583 shares — an estimated $3.13M sold.

PEAK6 first reported a position in MRNA in Q4 2024 and held it in 6 quarters. The position peaked at $8.67M in Q2 2025. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • PEAK6 reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • PEAK6 sold 60,583 Moderna shares in Q2 2026, an estimated $3.13M.
  • PEAK6 first reported a position in Moderna in Q4 2024 and held it in 6 quarters.
  • PEAK6's Moderna position peaked at $8.67M in Q2 2025.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.